设计,合成和评估了一组三环吩噻嗪(6a,6b和7a-1)和吩硒嗪(12a,12b和13a-1),作为针对阿尔茨海默氏病的胆碱能,淀粉样蛋白和氧化应激途径的多目标配体。吩噻嗪衍生物7j(2-氯-10 H-吩噻嗪-10-基-(4-甲氧基苯基)甲酮)被确定为最佳的双重非选择性胆碱酯酶抑制剂(AChE IC 50 = 5.9±0.6μM; BuChE IC 50 = 5.3±0.5μM),而在相应的吩硒嗪系列中,13j(2-氯-10 H-phenoselenazin-10-yl-((4-methoxyphenyl)methanone)表现出良好的非选择性胆碱酯酶抑制作用(AChE IC 50 = 5.8±0.4μM; BuChE IC 50 = 4.9±0.5μM)。有趣的是,N-10未取代的吩噻嗪6a(AChE IC 50 = 7.3±0.6μM; BuChE IC 50 = 5.8±0.5μM;Aβ1–42聚集抑制率=
Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer's disease
作者:Gary Tin、Tarek Mohamed、Nyasha Gondora、Michael A. Beazely、Praveen P. N. Rao
DOI:10.1039/c5md00274e
日期:——
A group of tricyclic phenothiazines (6a, 6b and 7a–l) and phenoselenazines (12a, 12b and 13a–l) was designed, synthesized and evaluated as multi-targeting ligands aimed at the cholinergic, amyloid and oxidative stress pathways of Alzheimer's disease. The phenothiazine derivative 7j (2-chloro-10H-phenothiazin-10-yl-(4-methoxyphenyl)methanone) was identified as the best dual, non-selective cholinesterase
设计,合成和评估了一组三环吩噻嗪(6a,6b和7a-1)和吩硒嗪(12a,12b和13a-1),作为针对阿尔茨海默氏病的胆碱能,淀粉样蛋白和氧化应激途径的多目标配体。吩噻嗪衍生物7j(2-氯-10 H-吩噻嗪-10-基-(4-甲氧基苯基)甲酮)被确定为最佳的双重非选择性胆碱酯酶抑制剂(AChE IC 50 = 5.9±0.6μM; BuChE IC 50 = 5.3±0.5μM),而在相应的吩硒嗪系列中,13j(2-氯-10 H-phenoselenazin-10-yl-((4-methoxyphenyl)methanone)表现出良好的非选择性胆碱酯酶抑制作用(AChE IC 50 = 5.8±0.4μM; BuChE IC 50 = 4.9±0.5μM)。有趣的是,N-10未取代的吩噻嗪6a(AChE IC 50 = 7.3±0.6μM; BuChE IC 50 = 5.8±0.5μM;Aβ1–42聚集抑制率=